

119TH CONGRESS
2D SESSION

S. 3598

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

IN THE SENATE OF THE UNITED STATES

JANUARY 8 (legislative day, JANUARY 7), 2026

Mrs. SHAHEEN (for herself and Ms. COLLINS) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To provide for the periodic issuance of up-to-date clinical guidance on addressing the health effects of per- and polyfluoroalkyl substances (PFAS), and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Better Care for PFAS
5 Patients Act of 2026”.

1 **SEC. 2. PFAS HEALTH EFFECTS ASSESSMENT, REC-**
2 **COMMENDATIONS, AND GUIDANCE.**

3 (a) PERIODIC ASSESSMENT AND RECOMMENDA-
4 TIONS.—

5 (1) AGREEMENT.—The Director of the Agency
6 for Toxic Substances and Disease Registry (in this
7 section referred to as the “Director”) shall enter
8 into an agreement with the National Academies of
9 Sciences, Engineering, and Medicine (or another ap-
10 propriate entity if the National Academies declines
11 to enter into such agreement) under which the Na-
12 tional Academies or the other appropriate entity
13 agrees—

14 (A) to assess the health effects of per- and
15 polyfluoroalkyl substances (in this section re-
16 ferred to as “PFAS”) that can be measured in
17 human tissues;

18 (B) to formulate clinical recommendations
19 on addressing such health effects;

20 (C) not later than 2 years after the date
21 of entry into such agreement, to complete the
22 initial assessment under subparagraph (A) and
23 formulate the initial recommendations under
24 subparagraph (B); and

25 (D) to update the most recent assessment
26 and recommendations under this paragraph—

- 1 (i) every 5 years; or
2 (ii) more frequently as determined
3 necessary by the Director based on an as-
4 sessment of the science.

5 (2) CONSULTATION.—In carrying out the as-
6 sessments under paragraph (1), the National Acad-
7 emies of Sciences, Engineering, and Medicine or
8 other appropriate entity shall engage with PFAS ex-
9 posed communities and solicit input from members
10 of such communities regarding their experiences
11 with PFAS exposure, testing, and clinical follow-up.

12 (3) TIMING OF ENTRY INTO AGREEMENT.—The
13 Director shall enter into the agreement required by
14 paragraph (1) not later than 60 days after the date
15 of enactment of this Act.

16 (b) UP-TO-DATE GUIDANCE.—Based on the results
17 of the most recent assessment and recommendations
18 under subsection (a), the Director, in consultation with
19 the entity with which the Director enters into the agree-
20 ment under subsection (a), shall—

21 (1) not later than 5 years after the date of
22 entry into the agreement required by subsection
23 (a)—

24 (A) issue up-to-date clinical guidance on
25 addressing the health effects of PFAS;

1 (B) post such guidance on the public
2 website of the Agency for Toxic Substances and
3 Disease Registry; and

4 (C) disseminate such guidance to State
5 and local public health authorities and appro-
6 priate health care professionals; and

7 (2) every 5 years thereafter, or more frequently
8 as determined necessary by the Director based on an
9 assessment of the science, issue, post, and dissemi-
10 nate up-to-date guidance as described in paragraph
11 (1).

○